---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-002728"
form_type: "8-K"
ticker: "KZR"
cik: "0001645666"
company_name: "Kezar Life Sciences, Inc."
filed_at: "2024-01-08T23:59:59+00:00"
generated_at: "2026-06-07T02:21:45.269122+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Kezar Life Sciences preliminarily estimates $201.4M cash, 72.8M shares as of Dec 31, 2023

## Summary
- Preliminary cash, cash equivalents and marketable securities of approximately $201.4 million as of December 31, 2023.
- Common stock outstanding estimated at 72.8 million shares as of December 31, 2023.
- Estimates are unaudited and may change after completion of year-end closing and auditing procedures.

## SEC filing metadata
- accession: 0000950170-24-002728
- form_type: 8-K
- ticker: KZR
- cik: 0001645666
- company_name: Kezar Life Sciences, Inc.
- filed_at: 2024-01-08T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 2.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645666/000095017024002728/0000950170-24-002728-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645666/000095017024002728/kzr-20240108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-002728
- JSON: https://secwatch.observer/filing/0000950170-24-002728.json
- Plain text: https://secwatch.observer/filing/0000950170-24-002728.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.